Moderna Stock News

Moderna said on Thursday it secured a five-year loan of $1.5 billion from Ares Management , as it targets up to 10% revenue growth next year.

Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026 Expects to expand seasonal vaccine franchise from three to up to six approved products by 2028 Targets readouts from nine ongoing Phase 2 and Phase 3 clinical studies in its oncology pipeline, including three Phase 3 programs for intismeran autogene Further improves 2026 and 2027 exp...

Non-dilutive financing from premier lender bolsters strong balance sheet and provides increased flexibility Company reiterates 2025 financial guidance provided on 3Q25 earnings call and targets cash breakeven by 2028 CAMBRIDGE, MA / ACCESS Newswire / November 20, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced it has closed a five-year term loan facility for up to $1.5 billion of capital fro...

Moderna said on Wednesday it would now operate full end-to-end manufacturing for its mRNA medicines in the U.S., marking a major step in strengthening the company's domestic production network.

New capabilities strengthen U.S. production, completing Moderna's domestic end-to-end mRNA manufacturing network More than $140 million investment will create hundreds of highly skilled biomanufacturing jobs CAMBRIDGE, MA / ACCESS Newswire / November 19, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced the expansion of its U.S. manufacturing capabilities with the onshoring of Drug Product man...

CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / November 18, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conference: Piper Sandler's 37th Annual Healthcare Conference, on Tuesday, December 2nd at 11:00am ET A live webcast of each of the presentation will be available under "Events and Presentations" in the Investors section of the Modern...

Moderna (MRNA) stock has reached day 5 of a consecutive winning streak, with total gains during this time reaching a 13% return. The company's value has increased by approximately $1.2 billion over the last 5 days, leading to a current market capitalization of around $10 billion.

Initiated stake: 500,000 shares, an estimated $12.91 million increase Post-trade Moderna position: 500,000 shares, valued at $12.91 million Moderna now accounts for 1.23% of Telemark's reportable AUM, which places it outside the fund's top five holdings